GlobeNewsWire
16 Sept 2026, 12:46 UTC · 1h ago
Verdict
Headline takes no side. We score NTHI +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
NeOnc's NEO100 Phase 2a study met its primary endpoint with a six-month progression-free survival of 48.9% against a 20% benchmark.
Priced inresults announced on August 12
So whatThe p-value of 0.0047 suggests high statistical significance, reducing the risk of a Phase 3 failure.
More positive than 98% of claims this week
Two senior executives purchased approximately $629,000 in open-market shares since August 12, with the most recent purchase occurring on September 15.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newpurchase on September 15, published September 16
So whatThe CEO's personal stake now exceeds $1.5 million, aligning management interests with shareholders for the FDA filing.
More positive than 85% of claims this week
NeOnc recently announced a $15 million registered direct offering to fund its clinical programs.
Priced inarticle says "recently announced"
So whatThis capital infusion extends the runway for the NEO212 program as it transitions to Phase 2.
More positive than 65% of claims this week
The second program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose.
Priced inno timing evidence provided
So whatEstablishing a Phase 2 dose provides a secondary catalyst if NEO100 faces regulatory delays.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Positive Phase 2a clinical results, significant insider buying by executives, and successful capital raising.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
9h ago
—
NTHI hasn't traded since this ran. Last close $3.31 (Sep 15); the reaction starts at the next open.
NTHI chart →
